Roche Holding : After a decline in 2020, EPS should mark time in 2021
>No growth in prospect in Swiss francs in 2021 - In a challenging context (biosimilars, coronaviruses), Roche met its 2020 target by publishing yesterday EPS growth of 4% at constant currency (cc). However, the strong currency effect (-9% on EPS) saw the company publish core EPS down 5%. While the company is logically renewing its ambitions for 2021 (growth at low to mid-single digit for sales and EPS at cc) in a similar context, it is still expecting adverse currenc...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.